Archive | October, 2016

Hot Investor Mandate 4: Corporate VC Focuses on Preclinical Oncology Therapeutics

13 Oct

A $50 million strategic corporate venture capital fund formed by a pharmaceutical company headquartered in Japan seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The fund is currently seeking opportunities in the U.S., Europe and Japan.

The firm considers all modalities of oncology therapeutics with a special interest in biologics. The firm focuses on programs from drug discovery to preclinical development. The firm is looking for assets that have a strategic angle to its parent company’s pipeline.

The firm is looking for teams with strong sector expertise. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Behind the Curtain of RESI Partnering

6 Oct

Natasha Eldridge, Marketing Manager – RESI Conference Series, LSN

Organizing RESI Partnering was an amazing experience for me, and with the help of Alisdair Stamps from Meeting-Mojo, RESI Boston successfully had more than 1,300 meetings.

Now, I would like to remove the curtains as the Wizard of Oz or RESI and share a few tips on what I learned about partnering and getting meetings with investors.

Investor Profiles Are Filled Out in Depth

I have been to many partnering conferences and rarely see investor profiles filled out besides the name of the attendee representing the firm. A strong differentiator of the RESI Conferences is LSN’s ability to populate investor profiles with their up-to-date investment preferences and criteria. The reason for this is to help fundraising companies make the most of their time by meeting with the right investors.

Through the search options, you can find investors that are actively investing in your technology type, indication, and phase of development. You don’t have to imagine a list of investors looking specifically for your asset(s) because we put that list together for you.

It’s a Numbers Game

One request to a few investors is not going to cut it. You can generate your list by using the search function – now use it.  Research and message the entire list of investors.  At LSN, sometimes we have to contact investors 5, 10 or 25 times to get a response, and we know the investors! Don’t be disappointed if you do not hear from an investor immediately.  They may be very distracted by other matters, or out of the office on a trip. The point is they are busy, so keep messaging them until you get a response.

Partnering Requests Are a 10-Second Pitch, Not a 350-Page Novel

Actually, according to a recent study by Microsoft most people have an attention span less than a goldfish, or just 8 seconds. Now that you know an investor might spend about 8 seconds reading your request, what do they need to know about your company. Well, it only takes these 6 key elements to get your message across in a short amount of time.

1st — Introduce Yourself

Introduce yourself, your title, and the name of your company. Although obvious, you might be surprised by how many people don’t do this.

2nd — Introduce Your Company

Give a brief overview of your company so that an investor can determine from the first sentence whether you are a fit for their investment mandate. Remember, every investor is unique and therefore not every investor is a fit for your opportunity. Here are five key data points that are likely to affect investor fit:

Where your company is based

What sector your company is in (biotech, medtech, diagnostics, healthcare IT, etc)

The modality you are using

The indication you are treating or problem you are trying to solve

Your product’s development phase

3rd — Key Value Proposition/Elevator Pitch

Use the next part of the email to describe the key value proposition of your technology. This should include a high-level description of the core technology and its major differentiators from currently available products or solutions. This is the core of your messaging and should reveal enough information to pique interest.

4th — The Stage of Your Fundraising Campaign

You should clearly state where you are in the fundraising process (beginning, middle or end) and what the use of those proceeds will be. This way an investor can gauge if your round is a fit for their capital allocation.

5th — Reaffirm

You should do your homework on every investor you reach out to and reference a relevant data point to reaffirm the reason you are reaching out.

6th — The Next Step

Finish the email by laying out when you plan on connecting with them and how the both of you should connect. As this is a conference partnering message, this can be as simple as telling them to accept the meeting request if they would like to meet up.

By sticking to these fundamentals you will make it a lot easier for an investor to identify you as a fit for their investment strategy. This will lead to higher response rates and more productive meetings.

Company Marketing Materials Need to be On Point

Take a look at your marketing material. Is it full of graphs, charts and before & after pictures of mice? Can an investor immediately identify the value proposition of the company and products? Humans relate to stories and investors are the same. Make sure your charts, graphs and pictures (and words) are creating an amazing story about your assets. Again, do not create a novel to tell your story. Stick with a maximum 2-page Executive Summary and 10-12-page PowerPoint Pitch Deck.

So What, You Had a Few Scheduled Meetings? Ad-Hoc Meetings Matter

I have spoken with several investors who enjoy meeting companies on the fly, after a panel session, or during the cocktail reception. I have also spoken with several companies who got funded by talking to investors companies on the fly, after a panel session, or during the cocktail reception. Either way investors and fundraising companies are using the RESI Conference to build relationships. Sometimes you will hit it out the park on your first time at bat or first RESI Conference and get funded and sometimes you need a few more times at the plate to get your first hit or attend several RESI Conferences to meet the right investor.

Partnering opens for RESI San Francisco on December 5th. Take this time to get prepared and I will see you in San Francisco.

162801425610010374

RESI San Francisco Panel Announcement: Healthcare IT

6 Oct

By Lucy Parkinson, Director of Research, LSN

The healthcare investment world is just over 90 days out from the annual San Francisco conference week, and investors are already inking their plans for a busy week. Within that hectic JPM ecosystem, RESI SF is a key venue to meet with early stage startups, and many investors are already made their plans to attend.

LSN would like to make our first RESI San Francisco panel announcement: Healthcare IT Investors.  This panel focuses on investors that are looking for innovative startups using software to solve healthcare problems, from drug discovery and development to care provision and management. Significant investment is pouring into this sector, with an estimated $4.5 billion invested in 2015. At RESI, we’ll hear from 5 highly active investors from a diverse variety of firms on what they’re looking for in healthcare IT at present, and how an opportunity can catch their attention.

The participants will be:

Join us at RESI to hear from these experienced investors discuss how they search for and assess healthcare IT opportunities, and what areas of this diverse sector are most attractive at present.

162801425610010374

Life Science Financing Rounds Report: See the Latest Biomed Deal Stats

6 Oct

By Nono Hu, Director of Marketing, LSN

Hot off the press in September, LSN’s partners at Venture Valuation have created a report on life science financing round data from around the world.

This free report summarises every recorded round that took place in August, and provides summaries of the investment sizes, stages and the hottest areas for life science investment, along with highlights of the most significant financings.

This information is based on reports from dozens of bioclusters worldwide, in addition to the work of a team of analysts focused on early stage life science startups. Subscribers to the LSN Company Platform can access all this information directly.

You can read the report here: “Biotech Financing Summary“.

Hot Investor Mandate 1: Family Office Invests in Growth Stage Medtech and HCIT

6 Oct

A family office located in New York City makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor.

The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit.

The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Asia-Based Pharma Seeks Partnerships in Inflammation and Dermatology Drugs and Surgical Devices

6 Oct

A specialty pharmaceutical company headquartered in Tokyo, Japan focuses on pharmaceuticals, medical devices, and agro-veterinary products. The firm has strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The firm is currently seeking R&D collaboration and in-licensing opportunities globally as well as Japan-local marketing alliance.

Currently the firm is looking for innovative therapeutic products in the following areas: orthopedics with a focus on inflammation and pain, including RA/OA/arthritis pain/low-back pain; dermatology including dermatitis/acne/psoriasis; and mycology including topical and systemic treatments. The firm is also interested in peri-surgical medical devices as well as ophthalmology and niche market products.

The firm seeks to partner with publicly and privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Evergreen Fund Invests in Early Stage Devices, Therapeutics, and Diagnostics

6 Oct

An early-stage investment and development firm located in the US Mountain West has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1M – $3M range.

The firm invests in medical devices, therapeutics, diagnostics and research tools. RCT focuses on medical devices that can be approved under the 510(k) guidelines, and prefers therapeutic product generating platforms and research tools platforms. For therapeutics, RCT prefers investments at an early-stage, from pre-clinical up to Phase I.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com